

KEYWORD INDEX**WILEY**

4-Phenylbutyric acid, 604

A

A20, 172
 ABCC2 protein, 128
 actin cytoskeleton, 539
 acute cerebral infarction, 324
 acute kidney injury, 1069
 acute lung injury, 883
 adipogenesis, 930
 adiponectin, 819
 adjuvanticity, 448
 adriamycin, 411
 ADRM1, 47
 airway inflammation, 1113
 AKT1, 1077
 alanine aminotransferase, 819
 alcoholic fatty liver disease, 718
 Alzheimer's disease, 730
 amyloid precursor protein, 730
 angiogenesis, 686, 1101
 antiangiogenesis, 643
 anticancer cellular immunotherapy, 749
 anti-cancer drug, 166
 apigenin, 583
 APOC1, 419
 apoptosis, 92, 121, 200, 286, 324, 562, 675
 ARID1A, 940
 ARPE-19, 101
 asthma, 1113
 astragaloside, 718
 Astragaloside IV, 236
 astragalus polysaccharide, 1089
 ATG protein, 166
 ATG3, 468
 autophagy, 12, 136, 166, 314, 709

B

BACH1, 1048
 B-cell translocation gene 2, 973
 bladder cancer, 128
 BNIP3, 1089
 BRD4, 583

breast cancer, 572
 Budd-Chiari syndrome, 355

C

Calcium carbonate, 411
 cancer, 749
 cancer-related mortality, 63
 capsaicin, 128
 CASC2, 268
 ccRCC, 192
 CD127, 520
 CD4 + CD25+ Treg, 520
 cell cycle, 547, 872
 cell growth, 208
 cell proliferation, 111, 547
 cell survival, 121
 cerebral ischemia-reperfusion injury, 468
 cervical cancer, 402, 547, 699, 964, 1058
 cervical carcinoma, 583
 chemosensitivity, 709
 cholangiocarcinoma, 379
 chondrocytes, 27
 chondroitin sulfate, 411
 chronic, 245
 chronic hepatitis C, 334
 chronic lymphocytic leukemia, 226
 circ_0000317, 951
 circ_0000517, 1027
 Circ_0000730, 964
 circ_0011385, 1058
 circ_0087862, 1048
 circRNA, 803
 circRNA_101996, 547
 circular-PRKDC, 392
 circ-ZNF609, 686
 cisplatin, 505
 c-Jun/AIF1 axis, 594
 clear cell renal cell carcinoma, 121, 419, 973
 CLIC1, 226
 clopidogrel, 1010
 c-Myc, 759
 colchicine, 616
 colitis, 795
 collagen-induced arthritis, 604
 colorectal cancer, 1048

congenital Porto-systemic shunts, 355
 COPD, 594
 coronary artery calcification, 624
 coronary atherosclerotic heart disease, 1038
 coronary heart disease, 314
 CRC, 951
 circ_0000064, 841
 CRP, 1000
 CTRP3, 324
 CUL4B, 664
 Cullin 4B, 121
 curcumin, 513

D

DAAs, 334
 damage-associated molecular patterns, 448
 DANCR, 371
 dendritic cells, 594
 dental calculus, 910
 depression, 903
 dextran sodium sulfate, 497
 diabetic cardiomyopathy, 136
 diabetic retinopathy, 101
 diagnosis, 730
 diagnostic markers, 1038
 direct acting antivirals, 145
 discovery, 7
 disease burden, 262
 DMFT index, 910
 DNMT3a, 594
 double primary malignancy, 63
 dual-specific phosphatase 1, 883

E

E2F3, 92
 elimination, 7
 endometriosis, 776
 endoplasmic reticulum, 604
 endothelial cells, 1101
 entitlement, 903
 epilepsy, 803
 epithelial mesenchymal transition, 419
 epithelial-mesenchymal transition, 784

- ERBB4, 111
 eriodictyol, 812
 errors of omission, 82
 ESR, 1000
 evidence-based medicine, 55
 exosome, 305
 exosomes, 226, 973
 EZH2, 513
- F**
- Five-item brief symptom rating scale
 (BSRS-5), 427
 focal nodular hyperplasia, 355
 Fontan-associated liver disease, 355
 foot processes, 539
 formononetin, 215
 Foxp3, 520, 1000
 frustration intolerance, 903
 FZR1, 991
- G**
- Gallbladder carcinoma, 294
 gamma-glutamyl transpeptidase, 819
 GAS5, 479, 776, 940
 gastric cancer, 111, 208, 305, 709, 759
 gastric carcinoma, 215, 863
 GC, 841
 gemcitabine resistance, 128
 gene knockout, 487
 general hospital, 427
 genotype 2, 334
 glioma, 851
 glycolysis, 759, 1027
- H**
- HADSC, 1077
 HCC, 643
 HCV, 7, 334
 HDAC10, 402
 HDAC4, 1069
 hepatitis B virus, 262, 894
 hepatitis C, 245
 hepatitis C virus, 145, 894
 hepatocellular carcinoma, 47, 145, 262,
 616, 784, 894, 991
 hereditary Haemorrhagic telangiectasia, 355
 Herp, 487
- HIF-1 α , 1089
 high-fat diet, 487
 HOXA1, 276
 HOXD10, 951
 human periodontal ligament fibroblasts, 38
 HUVECs, 226
 hypaphorine, 883
 hypertension, 236
 hypoxia/reoxygenation, 92
- I**
- Immune checkpoint blockade, 448
 immune checkpoint inhibitors, 643
 immunogenic cell death, 448
 immunotherapy, 616
 inducer, 166
 inflammation, 136, 192, 236, 883
 inflammatory bowel disease, 497
 inflammatory response, 200
 inhibitor, 166
 inpatients, 427
 interleukin-1 receptor-associated kinase
 1, 497
 internet gaming disorder, 903
 invasion, 20, 181, 215, 268, 276, 286, 361,
 402, 459, 562, 699, 863
- J**
- JAK2/STAT3 pathway, 468
 JAZF1, 572
- L**
- LINC01315, 459
 lipid accumulation, 718
 liver cirrhosis, 245
 liver transplantation, 910
 LMX1B, 851
 lncRNA, 479, 940
 lncRNA CASC2, 675
 lncRNA CCAT1, 654
 lncRNA H19, 101
 lncRNA MIAT, 1038
 lncRNA RMRP, 468
 lncRNA SNHG1, 181
 lncRNA UCA1, 172
 lncRNA-NEF, 930
 long non-coding RNA TP73-AS1, 361
- long non-coding RNA-H19, 768
 LPS, 1069
 lung adenocarcinoma, 675
 lung cancer, 411, 505
- M**
- M1 phenotype, 749
 macrophages, 749
 α -mangostin, 709
 MAPK pathway, 654
 MEC-1, 226
 melanoma, 55
 meta-analysis, 55
 metabolic syndrome, 12, 819
 metastasis, 192
 methylation, 520
 microRNA, 479, 497, 776
 microRNA-106, 27
 microRNA-140, 768
 microRNA-15a, 973
 microRNA-217, 121
 microRNA-29b-3p, 1038
 microRNA-495, 361
 microRNA-613, 468
 MicroRNA-653-5p, 392
 microRNAs, 111
 migration, 20, 181, 215, 276, 361
 miR-101-3p, 664
 miR-10a-5p, 276, 784
 miR-1236-3p, 547
 miR125a, 172
 miR-125b-5p, 863
 miR-128-3p, 795
 miR-140, 38
 miR-142-3p, 1048
 miR-145, 686
 miR-146a, 286
 miR-147a, 1101
 miR-149-3p, 1077
 miR-149-5p, 1058
 miR-152-5p, 583
 miR-155, 930
 miR-181a, 200
 miR-186-5p, 379
 miR-188-5p, 294
 miR-1908, 402
 miR-192-5p, 699
 miR-195, 181
 miR-19b, 101
 miR-200b, 572
 miR-202, 730

- miR-206, 1089
miR-21, 675
miR-29b-3p, 1069
miR-30a-5p, 92
miR-3129-5p, 314
MiR-31-5p, 940
miR-3175, 20
miR-330-5p, 1027
miR-409-3p, 324
miR-483-5p, 192
miR-485-5p, 851
MiR-497-5p, 459
miR-520g, 951
miR-542-5p, 215
miR-621, 841
miR-671-5p, 983
miR-936, 111
miR-942-5p, 964
miRNA-495, 562
missed care, 82
MPHOSPH9, 208
MsPGN, 872
mTOR, 208, 314
MyD88, 1101
- N**
- NAFLD, 487
nasopharyngeal carcinoma, 361, 686
NEAT1, 379
next-generation sequencing, 803
NF- κ B, 172, 795, 812
NF- κ B signaling pathway, 572
NNMT, 305
Nobel Prize, 7
nonalcoholic fatty liver disease, 819
noncoding RNA, 776
non-small cell lung cancer, 654
Notoginsenoside R1, 1101
NOVA1, 286
NSCLC, 664, 1027
NSUN2, 991
nursing, 82
- O**
- Oesophageal cancer, 181
oleanolic acid, 505
oral hygiene, 910
osteoarthritis, 27
osteogenesis, 930
osteogenic differentiation, 38, 1077
osteoporosis, 513
ovarian cancer, 276, 371, 768
ovarian clear cell carcinoma (OCCC), 940
oxidative stress, 136, 718
- P**
- P38/JNK signaling, 294
pancreatic cancer, 562
panoramic radiography, 910
papillary thyroid cancer, 459
papillary thyroid carcinoma, 983
PAPPA, 1038
pathway analysis, 803
patient safety, 82
PCNA, 872
peritoneal metastasis, 305
phytochemicals, 128
PI3K/AKT, 379, 664
PI3K/AKT pathway, 973
PI3K/AKT/mTOR signaling, 392
podocytes, 539
preeclampsia, 236
prognosis, 55, 208
prognostic, 419
progression, 371
proliferation, 20, 27, 268, 294, 675,
699, 709, 759, 768, 863,
872, 964
proteasome, 47
proteinuria, 539
psoriasis, 172
psychological distress, 427
PTEN, 930, 964
PTP4A1, 379
- R**
- RA190, 47
radiosensitivity, 654
radiotherapy, 654
rational emotive behavior therapy, 903
rats, 795
recurrent pregnancy loss, 479
Reelin, 392
retinoblastoma, 286
rheumatoid arthritis, 604
RhoA, 38
- risk factor, 55
RYBP, 863
- S**
- S100P, 562
SCN4B, 20
secretory autophagy, 12
sepsis, 200, 883, 1069
silica nanoparticle, 505
SIRT1, 101, 200
SKA1, 784
skimmin, 136
SNHG12, 664
SNHG3, 851
SOCS-3, 872
Sorafenib, 145, 616, 894
SOX4, 1058
SP1, 371
statins, 624
steroid-induced osteonecrosis of the femoral
head, 1089
STMN1, 686
suicide ideation, 427
survival, 145
SYF2, 841
synovial fibroblast, 604
systemic treatment, 643
- T**
- Taiwan, 245, 334
target therapy, 616
TAZ, 38
T-cell acute lymphoblastic leukemia,
392
TGF- β 1, 1000
Th17, 1113
Th-17/Treg balance, 594
therapeutics, 245
thyroid cancer, 63, 268
ticagrelor, 1010
tirofiban, 1010
TNBS, 812
toll-like receptor 4, 812
TRAF6, 795
Treg, 1000, 1113
TRIM14, 983
TRPM7, 699
tumor suppressor, 983

U

Ulcerative colitis, 497, 812
unmet nursing needs, 82
unstable angina pectoris, 1010

V

Vitamin D, 1113
vitamin K-dependent proteins, 624
vulvar lichen sclerosus, 520

W

Wnt1, 768
Wnt3a/ β -catenin pathway, 27
Wnt/ β -catenin, 513
Wnt/ β -catenin signaling, 294

X

Xenografts, 851

Y

YY1, 1027

Z

ZNF479, 759